Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Starts China Trials for Gastric Cancer and Breast Cancer Treatments

publication date: Feb 4, 2020

Shanghai's Zai Lab has started two China clinical trials: a Phase I combination test of Zezula (niraparib), a PARP inhibitor, paired with a bi-specific PD-1 for gastric cancer, plus a bridging trial of margetuximab for HER2-positive breast cancer. Two months ago, Zai was granted its first China drug approval for Zezula (niraparib) as an ovarian cancer treatment. It will be administered together with a bispecific PD-1 x LAG-3 DART® molecule in-licensed from MacroGenics. The second trial will administer a HER2 mAb, margetuximab, to HER2-positive breast cancer patients. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: MGNX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.